Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Norovirus Bivalent Vaccine in Healthy People
NCT04188691Phase 1Completed
- Sponsor
- Serum Institute of India
- Start
- Nov 2019
- Primary completion
- Dec 2020
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of recombinant norovirus bivalent (GI.1/GII.4) vaccine in norovirus infection (5 arms), sponsored by Serum Institute of India. Primary endpoints: Adverse Events at 30 minutes, Active Adverse Events and 2 more. Started Nov 2019; status: completed.
02
Drugs
recombinant norovirus bivalent (GI.1/GII.4) vaccine
03
Conditions
norovirus infection
Beyond the preview
Go deeper on NCT04188691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04188691.